7 results match your criteria GETGOAL program

  • Page 1 of 1

Lixisenatide, a Once-Daily Prandial Glucagon-Like Peptide-1 Receptor Agonist for the Treatment of Adults with Type 2 Diabetes.

Pharmacotherapy 2017 Aug 26;37(8):927-943. Epub 2017 Jul 26.

Pharmacy Practice, School of Pharmacy, MCPHS University, Boston, Massachusetts.

Lixisenatide, a short-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA), has been available in Europe since 2013 and was recently approved in the United States for the treatment of type 2 diabetes (T2D) as an adjunct to diet and exercise. The objective of this systematic review is to describe the pharmacology, pharmacokinetics, safety, and efficacy of lixisenatide in patients with T2D. We conducted a search of the EMBASE database, limited to human studies with abstracts available in English. Read More

View Article and Full-Text PDF

Lixisenatide Improves Glycemic Control in Asian Type 2 Diabetic Patients Inadequately Controlled With Oral Antidiabetic Drugs: An Individual Patient Data Meta-Analysis.

Diabetes Ther 2016 Dec 31;7(4):777-792. Epub 2016 Oct 31.

Department of Endocrinology, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing, China.

Introduction: Lixisenatide is a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus (T2DM). Its efficacy and safety have been assessed in a series of phase 3 studies included in the GetGoal program. In these studies, lixisenatide was found to be superior to placebo in glycemic control. Read More

View Article and Full-Text PDF
December 2016

Lixisenatide in type 2 diabetes: latest evidence and clinical usefulness.

Ther Adv Chronic Dis 2016 Jan;7(1):4-17

University of Colorado Anschutz Medical Campus, Skaggs School of Pharmacy and Pharmaceutical Sciences, Mail Stop C238, 12850 East Montview Blvd., Aurora, CO, USA.

Type 2 diabetes (T2D) is a highly prevalent disorder that affects millions of people worldwide. The hallmark of T2D is hyperglycemia and, while many treatment modalities exist, achieving and maintaining glycemic control can be challenging. Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are an appealing treatment option as they improve glycemic control, reduce weight, and limit the risk of hypoglycemia. Read More

View Article and Full-Text PDF
January 2016

Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis.

J Diabetes Complications 2014 Nov-Dec;28(6):880-6. Epub 2014 Jul 18.

Diabetes Research Centre, University of Leicester, Leicester, UK.

Aims: The efficacy of the once-daily prandial GLP-1 receptor agonist lixisenatide plus basal insulin in T2DM was assessed by pooling results of phase III trials.

Methods: A meta-analysis was performed of results from three trials in the GetGoal clinical program concerning lixisenatide or placebo plus basal insulin with/without OADs. The primary endpoint was change in HbA1c from baseline to week 24. Read More

View Article and Full-Text PDF

The clinical development program of lixisenatide: a once-daily glucagon-like Peptide-1 receptor agonist.

Authors:
Stephen C Bain

Diabetes Ther 2014 Dec 16;5(2):367-83. Epub 2014 Jul 16.

Institute of Life Science, College of Medicine, Swansea University, Swansea, SA2 8PP, UK,

Lixisenatide (AVE0010) is a once-daily glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type 2 diabetes. Phase II dose-finding and pharmacodynamic studies identified the 20 µg once-daily dose as having the optimum combination of efficacy, convenience and tolerability. Lixisenatide was prospectively investigated in a series of 11 multinational, randomised, controlled phase III trials (GLP-1 agonist AVE0010 in paTients with type 2 diabetes mellitus for Glycemic cOntrol and sAfety evaLuation [GetGoal] programme) that included a direct head-to-head study with exenatide. Read More

View Article and Full-Text PDF
December 2014

Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus.

Diabetes Metab Syndr Obes 2013 17;6:217-31. Epub 2013 Jun 17.

Department of Clinical Pharmacology, Bispebjerg Hospital, Copenhagen, Denmark.

The glucagon-like peptide (GLP)-1 receptor agonist lixisenatide (Lyxumia(®)) was approved for marketing by the European Medicines Agency in February 2013 and has been evaluated in a clinical study program called GetGoal. Lixisenatide activates the GLP-1 receptor and thereby exercises the range of physiological effects generated by GLP-1, which consist of increased insulin secretion, inhibition of glucagon secretion, and decreased gastrointestinal motility alongside the promotion of satiety. In the GetGoal study program, lixisenatide demonstrated significant reductions in glycated hemoglobin (HbA1c), and fasting and postprandial plasma glucose compared with placebo. Read More

View Article and Full-Text PDF

Lixisenatide: evidence for its potential use in the treatment of type 2 diabetes.

Core Evid 2011 8;6:67-79. Epub 2011 Sep 8.

University of Birmingham and BioMedical Research Centre, Heart of England National Health Service Foundation Trust, Birmingham, UK.

Lixisenatide is a once-daily glucagon-like peptide 1 (GLP-1) receptor agonist mimicking several favorable actions of endogenous GLP-1 that result in improved glycemic control with little or no hypoglycemia and weight loss. Phase II trials have shown that lixisenatide 20 μg once daily restores first-phase insulin release in patients with type 2 diabetes and improves the second-phase insulin response. Administered once or twice daily for 4 weeks, it significantly reduced postprandial and fasting blood glucose levels, and glycosylated hemoglobin (HbA(1c)). Read More

View Article and Full-Text PDF
November 2011
  • Page 1 of 1